You are viewing a free version of BCIQ, BioCentury's advanced business intelligence database for the biopharma industry.
Find partnering and investment opportunities, uncover and track competitive threats, dive into a company's financing and deal history, its pipeline and molecular targets of interest, and much more. Enter a Company name above to access free BCIQ profiles. Request a trial to unlock the full value of BCIQ.
University of California San Diego
Headquarters:La Jolla, CA
Year Founded:1960
Status:Academic
Biopharma related deals can be found by searching the organization's name in the BCIQ Deals Module*.*desktop version only

BioCentury | Nov 30, 2018

Company News

Genentech acquiring Versant-backed NASH play Jecure

...program would reach the clinic next year, according to its website. The company's scientific founder, University of California San Diego...

BioCentury | Jun 10, 2021

Deals

BeiGene picks iPS cells for its move into cell therapies via Shoreline deal

...January, also is developing iPS cell-derived NK cells.University of California San Diego...
...as well as CMO William Sandborn, a UCSD...

BioCentury | Apr 09, 2021

Translation in Brief

Two ways to reverse CAR T cell exhaustion; plus a ligand and its receptor in a single vector, Cleave, Amazentis and Cello

...A, to optimize muscle function.Cello’s membrane-coated nanoparticles improve efficacy of cancer therapyCello Therapeutics Inc. and University of California San Diego...
...Pharma Inc. Ikarovec Ltd. Institut National de la Sante et de la Recherche Medicale (INSERM) Cleave Therapeutics Inc. Amazentis S.A. University of California San Diego Cello...

BioCentury | Mar 13, 2021

Product Development

Long COVID therapies are starting to populate a sparse pipeline

...both ME/CFS and Long COVID. Researchers at University of California San Diego...

BioCentury | Mar 13, 2021

Translation in Brief

NIH identifies antisense oligos to treat progeria; plus epigenetic gene therapies for chronic pain and Cend’s pancreatic cancer therapy

...CEND-1, a cyclic peptide that promotes drug uptake by tumor cells. A team led by UCSD...
...voltage-gated channel alpha subunit 9 Danielle Golovin Gemzar, gemcitabine CEND-1 Imfinzi, durvalumab (MEDI4736) Lynparza, olaparib (AZD2281, KU-0059436, MK-7339) National Institutes of Health University of California San Diego Navega...

BioCentury | Feb 26, 2021

Distillery Therapeutics

Blocking COL1 for multiple sclerosis

...Francisco, San Francisco, Calif.email: thomas.arnold@ucsf.eduCONTACT: Richard Daneman, University of California, San Diego, La Jolla, Calif.email: rdaneman@ucsd.edu Claire Quang University of California San Diego University...

BioCentury | Feb 23, 2021

Distillery Therapeutics

Mir690, NADK as targets in insulin resistance

...14, 2021doi:10.1016/j.cmet.2020.12.019CONTACT: Wei Ying, University of California San Diego, San Diego, Calif.email: weying@health.ucsd.eduCONTACT: Jerrold M. Olefsky, same affiliation as aboveemail: jolefsky@health.ucsd.edu Claire Quang University of California San Diego NAD...

BioCentury | Jan 30, 2021

Distillery Therapeutics

Epigenetic repressors of repetitive elements as cancer targets

...available for partneringPUBLICATION DETAILS: Shen, J. et al. Cell; published online Dec. 23, 2020doi:10.1016/j.cell.2020.11.042CONTACT: Jeremy N. Rich, University of California San Diego...
...Spruck, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, Calif.email: cspruck@sbpdiscovery.org Claire Quang Sanford Burnham Prebys Medical Discovery Institute University of California San Diego Suppressor...

BioCentury | Jan 23, 2021

Translation in Brief

Ionis’ ASO therapy for MM; plus epigenetic modification prevents myeloma-associated bone loss and bryostatin analogs reduce neuroinflammation

...G9A) – Euchromatic histone-lysine N-methyltransferase 2 IRF4 – Interferon regulatory factor 4PKC – Protein kinase C Danielle Golovin University of California San Diego Ionis...

BioCentury | Dec 18, 2020

Regulation

FDA panel for mRNA-1273 highlights challenges ahead for COVID vaccine trial recruitment, retention

...Sawyer, professor of clinical pediatrics at the University of California San Diego.Separately...

BioCentury | Dec 12, 2020

Regulation

As U.S. joins U.K., Canada in authorizing BNT162b2 for COVID-19, all eyes turn to deployment

...Sawyer, professor of clinical pediatrics at the University of California San Diego...

BioCentury | Dec 11, 2020

Product Development

Pfizer-BioNTech COVID-19 vaccine endorsed at shambolic advisory committee meeting

...Sawyer, professor of clinical pediatrics at the University of California San Diego...

BioCentury | Sep 19, 2020

Translation in Brief

Gene therapies from Passage Bio, Locanabio; Lava’s antitumor bispecific, health disparities in Alzheimer’s and more

...see “Passage Bio Outlines Clinical Goals”).Locanabio’s RNA-targeting gene therapyScientists at Locanabio Inc, with collaborators at University of California San Diego...
...kinaseGRN – GranulinPGRN (PCDGF) - Progranulin TCR – T cell receptor Danielle Golovin PBFT02 Passage Bio Inc. University of Pennsylvania University of California San Diego University...

BioCentury | Sep 10, 2020

Finance

Korro Bio’s $91.5M series A brings in new investors, launches hunt for CEO

...based on the work of co-founder Prashant Mali, an assistant professor of bioengineering at the University of California San Diego.Behind...

BioCentury | Jun 27, 2020

Tools & Techniques

Tapping astrocytes to replace lost neurons in Parkinson’s

...regenerative medicine approach that involves transforming one cell type in the body into another, a University of California San Diego...
...share many features with glial cells, a family of cells that incudes astrocytes, making the UCSD...
...analogous to the hearing loss approaches. In a study p ublished in Nature , the UCSD...

BioCentury | Jun 23, 2020

Distillery Therapeutics

Repurposing antimalarial drug lumefantrine for glioblastoma

...published online May 14, 2020 doi:10.1073/pnas.1921531117 CONTACT: Webster K. Cavenee, University of California San Diego, La Jolla, Calif. email: wcavenee@ucsd.edu...
...mahitosh@smst.iitkgp.ac.in CONTACT: Paul B. Fisher, Virginia Commonwealth University School of Medicine, Richmond, Va. email: paul.fisher@vcuhealth.org Claire Quang University of California San Diego Virginia...

BioCentury | Jun 06, 2020

Translation in Brief

Engineered bacteria for targeted bacterial killing; plus Cas12a base editors, base editing to restore hearing and more

...Protein peptidylprolyl cis/trans isomerase NIMA-interacting 1 TMC1 - Transmembrane channel-like-1 Danielle Kopke, Staff Writer PDAC University of Washington University of California San Diego Harvard...

BioCentury | Jun 06, 2020

Management Tracks

COVID-19 vaccine partners Lonza and Moderna announce new execs; plus Samumed, EpicentRx, Immatics, Aligos, ImmunoGen, Ferring, Sanifit and more

...Tony Reid will become CEO. He is also an associate professor of oncology at the University of California San Diego...

BioCentury | May 01, 2020

Distillery Therapeutics

LAMP2 gene therapy for cardiomyopathy and liver dysfunction in Danon disease

...online March 18, 2020 doi:10.1126/scitranslmed.aax1744 CONTACT: Eric D. Adler, University of California San Diego, San Diego, Calif. email: eradler@health.ucsd.edu Claire Quang University of California San Diego Lysosomal-associated...

BioCentury | Feb 01, 2020

Preclinical News

Cellular fluorescence assay to assess allosteric modulator potency in drug discovery

...Karolinska, Pasteur and UCSD researchers have developed a cellular fluorescence assay that can efficiently screen for...
...values in glioblastoma cells (Pearson’s r = 0.62). Generation of the compounds was reported by University of California San Diego...
...Changeux is an emeritus professor of neuroscience at Institut Pasteur and a faculty member at University of California San Diego’s...

BioCentury | Dec 20, 2019

Tools & Techniques

Editing bacterial resistance via gene drives

...In a new take on combating antimicrobial resistance, a UCSD team developed a gene drive system...
...DNA (dsDNA) breaks is poor in some strains. In a Nature Communications paper published Monday, University of California San Diego...
...invention disclosure has been submitted to UCSD. Bier is a founder and board member at UCSD...

BioCentury | Dec 18, 2019

The proteasome-regulating kinase DYRK2 as a target in breast cancer and multiple myeloma

...published online Nov. 21, 2019 doi:10.1073/pnas.1912033116 CONTACT: Jack E. Dixon, University of California San Diego, La Jolla, Calif. email: jedixon@ucsd.edu...
...Peking University, Beijing, China email: junyuxiao@pku.edu.cn CONTACT: Xiaoguang Lei, same affiliation as above email: xglei@pku.edu.cn Claire Quang University of California San Diego Peking...

BioCentury | Dec 06, 2019

Company News

Management tracks: Cancer therapy pioneer Desmond-Hellmann leaving Gates Foundation; plus CStone, Janssen, Akcea, insitro and more

...SVP, CMO, effective Jan. 1. He was an associate professor of clinical medicine at the University of California San Diego...

BioCentury | Nov 21, 2019

Bacteriophages for alcoholic liver disease

...Schnabl, University of California San Diego, La Jolla, Calif.; VA San Diego Healthcare System, San Diego, Calif. e-mail: beschnabl@ucsd.edu Inhua Muijrers-Chen University of California San Diego U.S...

BioCentury | Nov 21, 2019

Emerging Company Profile

ShapeTx: Shaping up RNA editing

...on the work of Shape co-founder Prashant Mali, an assistant professor of bioengineering at the University of California San Diego...

BioCentury | Nov 15, 2019

Preclinical News

Nov. 14 Preclinical Quick Takes: Gut microbe-targeting phage for alcoholic liver disease; plus Cellectis, Biomica, University of Michigan and Rubius

...Bacteriophages for alcoholic liver disease In a study described in Nature , University of California San Diego researchers identified a...
...Major histocompatibility complex class I; STAT3 - Signal transducer and activator of transcription 3 BioCentury Staff University of California San Diego University...

BioCentury | Nov 13, 2019

Financial News

With $35M D round, EpicentRx aims to complete clinical testing of cancer immunotherapy

...at the University of California San Diego. Reid is the company’s CSO and an associate professor of oncology at UCSD...

BioCentury | Oct 25, 2019

Emerging Company Profile

Deep Genomics: Letting AI take the wheel

...of Michigan, The Hospital for Sick Children, Massachusetts General Hospital, Harvard Medical School and the University of California San Diego...

BioCentury | Oct 15, 2019

Company News

Management tracks: Browne out as Revance CEO; plus CytomX, Aligos, Angion, Savonix and Global Cancer Technology

...as CTO. Makale is assistant adjunct professor of radiation medicine and applied science at the University of California San Diego...

BioCentury | Sep 20, 2019

Emerging Company Profile

Divide & Conquer: short-circuiting tumor lines of communication

...hypothesis is still relatively new, it isn’t wholly new. For example, a group at the University of California San Diego...

BioCentury | Sep 20, 2019

Emerging Company Profile

Boundless Bio: designing cancer therapies around extrachromosomal DNA

...scientific founder Paul Mischel believes does not occur in healthy cells. Mischel, who is a University of California San Diego...
...Epidermal growth factor receptor KRAS (K-Ras); MYC (c-Myc) - v-myelocytomatosis viral oncogene homolog Lauren Martz, Associate Editor University of California San Diego Scripps...

BioCentury | Aug 21, 2019

Distillery Therapeutics

Targeting CAD or DHODH to inhibit pyrimidine synthesis for glioblastoma

...Jeremy N. Rich, University of California San Diego, La Jolla, Calif. email: drjeremyrich@gmail.com Claire Quang Aubagio, teriflunomide (HMR1726) buparlisib (BKM120) Tykerb, Tyverb, lapatinib (GW572016) University of California San Diego Dihydroorotate...

BioCentury | Aug 02, 2019

Distillery Therapeutics

Small molecules that prevent stress granule formation in ALS

...CONTACT: Gene W. Yeo, University of California San Diego, La Jolla, Calif. email: geneyeo@ucsd.edu Claire Quang Novantrone (Brand), mitoxantrone (Generic), Novantrone (Other) University of California San Diego TAR...

BioCentury | Jul 18, 2019

Finance

As funding dwindles, CIRM believes goals within reach

...Beach, Calif.). Also progressing into clinical trials soon are work by Stephanie Cherqui at the University of California San Diego...
...Calif. University of California Irvine, Irvine, Calif. University of California Los Angeles, Los Angeles, Calif. University of California San Diego...

BioCentury | Jun 14, 2019

Politics, Policy & Law

No more crickets: The biopharma industry must speak out against the Trump administration’s fetal tissue ban

...conditions as diverse as rheumatoid arthritis and hemophilia. In March, Larry Goldstein, director of the University of California San Diego...
...Institutes of Health (NIH), Bethesda, Md. Pharmaceutical Research and Manufacturers of America (PhRMA), Washington, D.C. University of California San Diego...

BioCentury | May 23, 2019

Finance

With new CEO, $55M A round, Locana readies RNA-targeting gene therapy for clinic

...Gene Yeo. Locana’s technology is based on work by co-founder Yeo and his colleagues at University of California San Diego...

BioCentury | May 08, 2019

Translation in Brief

New Therapeutic Targets and Biomarkers: April 2019

...treat diseases driven by NLR family pyrin domain containing 3 (NLRP3; NALP3; CIAS1) inflammasome activation University of California San Diego...

BioCentury | Apr 30, 2019

Distillery Techniques

Fecal microbiome-derived signature to detect NAFLD-related cirrhosis

...published online Mar. 29, 2019 doi:10.1038/s41467-019-09455-9 CONTACT: Rohit Loomba, University of California San Diego, La Jolla, Calif. email: roloomba@ucsd.edu Claire Quang University of California San Diego Liver...

BioCentury | Apr 16, 2019

Preclinical News

Mounting a mitochondrial attack to starve the inflammasome

...least one academic group is shutting down the protein’s upstream mitochondrial triggers. The approach, from University of California San Diego...
...itself with small molecules as therapeutic approach (see “NLRP3 Early and Often" ). Michael Karin’s UCSD...
...sordid advantage" to inhibiting NLRP3 directly vs. targeting the protein via the choline-mitophagy axis. The UCSD...

BioCentury | Apr 02, 2019

Distillery Techniques

Mouse model of acne for screening therapies

...published March 7, 2019 doi:10.1172/jci.insight.124687 CONTACT: George Y. Liu, University of California San Diego, La Jolla, Calif. e-mail: gyliu@ucsd.edu Hongjiang Li University of California San Diego Acne...

BioCentury | Mar 29, 2019

Targets & Mechanisms

AACR moves in a myeloid direction

...Sloan Kettering Cancer Center ; UCLA - University of California Los Angeles ; UCSD - University of California San Diego...

BioCentury | Mar 19, 2019

Distillery Therapeutics

New brain-penetrating RIPK2 inhibitor prodrug for GBM

...Research, La Jolla, Calif. email: schultz@scripps.edu CONTACT: Paul S. Mischel, University of California San Diego, La Jolla, Calif. email: pmischel@ucsd.edu...
...L. Lairson, The Scripps Research Institute, La Jolla, Calif. email: llairson@scripps.edu Hongjiang Li California Institute for Biomedical Research University of California San Diego Scripps...

BioCentury | Mar 08, 2019

Emerging Company Profile

Synbal: Gene driving on parallel tracks

...storage diseases. Ethan Bier, Valentino Gantz and Tsvi Goldenberg spun out Synbal Inc. from the University of California San Diego...
...is a professor of cell and developmental biology and Gantz is a research assistant at UCSD...
...Haifa, Israel University of California San Diego, La Jolla, Calif. Targets Cas9 - CRISPR-associated protein 9 Mark Zipkin, Staff Writer Synbal Inc. University of California San Diego Mucopolysaccharidosis cell...

BioCentury | Feb 07, 2019

Translation in Brief

Driving for rodents

...A gene drive-like system from a UCSD team could bring the creation of rodent models of...
...machinery between insects and mammals; and concerns about systems propagating uncontrollably through mammalian populations. The University of California San Diego...
...beyond the first generation. Author Kimberly Cooper, assistant professor of cell and developmental biology at UCSD...

BioCentury | Feb 06, 2019

Distillery Techniques

Disease models

...published online Jan. 23, 2019 doi:10.1038/s41586-019-0875-2 CONTACT: Kimberly Cooper, University of California San Diego, La Jolla, Calif. email: kcooper@ucsd.edu Mark Zipkin University of California San Diego CRISPR-associated...

BioCentury | Jan 30, 2019

Translation in Brief

3-D-printed scaffold for spinal injuries

...to develop the technology. Neurobiologist Mark Tuszynski teamed up with bioengineer Jacob Koffler at the University of California San Diego...
...and director of the UCSD Translational Neuroscience Institute. Koffler is an assistant project scientist at UCSD’s...
...500,000 patients suffering with chronic spinal cord injuries. UCSD has patented the technology. Michael Leviten, Senior Writer University of California San Diego Spinal...

BioCentury | Jan 23, 2019

Distillery Therapeutics

Neurology

...University of California San Diego, La Jolla, Calif. email: aap@ucsd.edu CONTACT: Seth M. Сohen, same affiliation as above email: scohen@ucsd.edu Claire...
...La Jolla, Calif. email: aap@ucsd.edu CONTACT: Seth M. Сohen, same affiliation as above email: scohen@ucsd.edu Claire Quang University of California San Diego Glyoxalase...

BioCentury | Dec 14, 2018

Financial News

Allen Insitute's immunology division launches with $125M, Lilly vet and five partners

...data and tools publicly available. Partners include Benaroya Research Institute at Virginia Mason (BRI); the University of California San Diego...
...said during the briefing. Allen Institute, Seattle, Wash. Jennie Walters Allen Institute Benaroya Research Institute Fred Hutchinson Cancer Research Center University of California San Diego University...

BioCentury | Dec 13, 2018

Preclinical News

Allen Institute's immunology division launches with $125M, Lilly vet and five partners

...data and tools publicly available. Partners include Benaroya Research Institute at Virginia Mason (BRI); the University of California San Diego...
...to recruit leadership, Bumol said during the briefing. Jennie Walters Allen Institute Benaroya Research Institute Fred Hutchinson Cancer Research Center University of California San Diego University...

BioCentury | Dec 07, 2018

Preclinical News

UCSD team offers access to newly identified antimalaria leads

...A University of California San Diego team has published openly 631 antimalaria compounds identified through a screening campaign, offering the...
...liver that can cause disease recurrence. Additionally, resistance to artemisinin-based combination therapies is rising, the UCSD...
...stages in the malaria parasite’s life cycle (see “GSK Researchers Identify Dual-Stage Antimalarials” ). Allison Johnson GlaxoSmithKline plc University of California San Diego Malaria...

BioCentury | May 04, 2021

Product Development

With an eye toward M&A, Vivace aims to establish POC for emerging solid tumor target TEAD

...Virtuoso Therapeutics Inc. in 2018. Vivace’s initial Hippo pathway programs, licensed from its scientific founders at University of California San Diego...
...and is also exploring its TEAD inhibitors in other indications. Because Vivace pivoted from the UCSD-originated...

BioCentury | Nov 27, 2018

Company News

Genentech acquiring Versant-backed NASH play Jecure

...program would reach the clinic next year, according to its website. The company's scientific founder, University of California San Diego...

BioCentury | Nov 21, 2018

Preclinical News

Gene recombination sheds light on Alzheimer's failures, suggests HIV drugs could help

...amyloid precursor protein (APP) variants from researchers at Sanford Burnham Prebys Medical Discovery Institute and University of California San Diego...
...play. The team is open to licensing and partnership possibilities. Mark Zipkin Sanford Burnham Prebys Medical Discovery Institute University of California San Diego Amyloid...

BioCentury | Nov 07, 2018

Emerging Company Profile

ABL bispecifics

...Advanced Institute of Science and Technology, Pohang University of Science and Technology, Seoul National University, University of California San Diego...

BioCentury | Oct 18, 2018

Distillery Therapeutics

Neurology

...published online August 6, 2018 doi:10.1038/s41592-018-0074-3 CONTACT: Mark Tuszynski, University of California San Diego, La Jolla, Calif. email: mtuszynski@ucsd.edu Mary Romeo University of California San Diego Spinal...

BioCentury | Oct 12, 2018

Emerging Company Profile

Spinogenix’s Spine Craft

...third-generation tetraethylene glycol derivative of benzothiazole aniline that it developed from prototype compounds in-licensed from University of California San Diego...
...traumatic brain injury, and unpublished preclinical data show similar results in Parkinson’s. A team at UCSD...
...Diego, Calif. University of California San Diego, La Jolla, Calif. Targets FLNA - Filamin A Allison Johnson, Staff Writer Amydis Inc. Spinogenix Inc. University of California San Diego Rho...

BioCentury | Sep 14, 2018

Preclinical News

UCSD researchers identify mechanism, target in NASH

...Researchers from the University of California San Diego have identified a key mechanism behind the pathogenesis of non-alcoholic steatohepatitis (NASH...
...SREBF2 lack obvious caspase cleavage sites. In a paper published Thursday in Cell , the UCSD...
...and fibrosis, and improved liver histological scores. Author Michael Karin, a professor of pharmacology at UCSD...

BioCentury | Sep 10, 2018

Distillery Therapeutics

Autoimmune disease

...published online Sept. 3, 2018 doi:10.1038/s41565-018-0254-4 CONTACT: Liangfang Zhang, University of California San Diego, La Jolla, Calif. email: zhang@ucsd.edu Jennie Walters University of California San Diego Interleukin-1...

BioCentury | Sep 07, 2018

Company News

How Deerfield, UCSD’s Poseidon Innovation will support early R&D, start-ups

...UCSD, with a $65 million commitment from the investment firm. A joint steering committee comprising UCSD...
...studies necessary to support an IND. Poseidon will have the option to license IP from UCSD...
...Management Co. L.P., New York, N.Y. University of California San Diego, La Jolla, Calif. Business: Other Chris Lieu Deerfield Management Co. L.P. University of California San Diego...

BioCentury | Sep 05, 2018

Company News

How Deerfield, UCSD’s Poseidon Innovation will support early R&D, start-ups

...UCSD, with a $65 million commitment from the investment firm. A joint steering committee comprising UCSD...
...studies necessary to support an IND. Poseidon will have the option to license IP from UCSD...
...show commercial potential. The university expects Poseidon's first round of funding in March 2019. The UCSD...

BioCentury | Sep 04, 2018

Preclinical News

Neutrophil mimics block cytokines behind RA inflammation

...while skirting toxicity risks related to inhibiting cytokines. In a Nature Nanotechnology study , the UCSD...
...found in rheumatoid synovium to treat RA, the authors wrote. Study author Liangfang Zhang, a UCSD...
...or macrophage membranes enables those nanoparticles to bind toxins, thereby preventing attacks on healthy cells. Jennie Walters University of California San Diego Interleukin-1...

BioCentury | Aug 30, 2018

Translation in Brief

Turning off the inflammasome

...In a July Nature paper , a team from the University of California San Diego identified CMPK2 as a potential...
...processes that are involved in disease progression, and maybe even in disease onset.” Michael Karin, University of California San Diego...
...and cancer. While the external and internal signals for NLRP3 inflammasome activity are known, the UCSD...

BioCentury | Aug 29, 2018

Distillery Therapeutics

Endocrine/Metabolic

...published online Aug. 22, 2018 doi:10.1126/scitranslmed.aah6324 CONTACT: Rafi Mazor, University of California San Diego, La Jolla, Calif. email: rmazor@ucsd.edu...
...Friedmann-Morvinski, Salk Institute for Biological Studies, La Jolla, Calif. email: dino@post.tau.ac.il Sandi Wong Salk Institute for Biological Studies University of California San Diego Matrix...

BioCentury | Aug 29, 2018

Distillery Therapeutics

Dermatology

...Health (NIH), Bethesda, Md. email: morasso@nih.gov CONTACT: J. Silvio Gutkind, same affiliation as above email: sgutkind@ucsd.edu Sandi...

BioCentury | Aug 22, 2018

Preclinical News

Inhibiting MMP2 reverses leptin resistance associated with obesity

...of MMP2 inhibitors to restore sensitivity to leptin and decrease weight gain in obese individuals. Sandi Wong University of California San Diego Leptin Leptin...

BioCentury | Aug 03, 2018

Targets & Mechanisms

Oxitope’s oxidation play

...A trio of papers from a UCSD group has found a connection between oxidized lipids and...
...rather than oxidized, LDL in blood. Witztum, who is a professor of medicine at the University of California San Diego...
...in all three (see “Figure: Calming Macrophages”). Figure: Calming Macrophages A trio of papers from University of California San Diego...

BioCentury | Jul 17, 2018

Distillery Therapeutics

Cancer

...University of California San Diego, La Jolla, Calif. email: dcarson@ucsd.edu CONTACT: Tomoko Hayashi, same affiliation as above email: thayashi@ucsd.edu Claire Quang University of California San Diego Toll-like...

BioCentury | Jun 22, 2018

Company News

UCSD launches bacteriophage treatment center

...The University of California San Diego launched the Center for Innovative Phage Applications and Therapeutics (IPATH) to develop bacteriophages to...
...cocktails against bacteria selected by UCSD, but will not make monetary contributions to the project, UCSD...
...“Showdown: Bacteria vs. Virus” ). IPATH is launching with $1.2 million in seed funding from UCSD...

BioCentury | Jun 21, 2018

Company News

UCSD launches bacteriophage treatment center

...The University of California San Diego launched the Center for Innovative Phage Applications and Therapeutics (IPATH) to develop bacteriophages to...
...cocktails against bacteria selected by UCSD, but will not make monetary contributions to the project, UCSD...
...“Showdown: Bacteria vs. Virus” ). IPATH is launching with $1.2 million in seed funding from UCSD...

BioCentury | Jun 07, 2018

Translation in Brief

New Therapeutic Targets and Biomarkers: May 2018

...AIBP; NAXE) In vitro and mouse studies suggest AIBP could help treat chemotherapy-induced neuropathic pain. University of California San Diego...

BioCentury | Jun 05, 2018

Distillery Therapeutics

Neurology

...online May 29, 2018 doi:10.1016/j.celrep.2018.04.110 CONTACT: Yury I. Miller, University of California San Diego, La Jolla, Calif. email: yumiller@ucsd.edu Jennie Walters University of California San Diego Apolipoprotein...

BioCentury | Jun 05, 2018

Distillery Therapeutics

Neurology

...published online May 9, 2018 doi:10.1126/scitranslmed.aam6651 CONTACT: Martin Marsala, University of California San Diego, La Jolla, Calif. email: mmarsala@ucsd.edu Alicia Parker University of California San Diego Spinal...

BioCentury | May 31, 2018

Preclinical News

TLR4 inhibitor could help treat chemotherapy-induced pain

...A Cell Reports study from researchers at University of California San Diego showed spinal injection of a toll-like receptor 4-binding...
...to increased inflammation in several inflammatory disorders and diseases such as non-alcoholic steatohepatitis (NASH). The UCSD...
...cisplatin-induced peripheral neuropathy, completely reversing established allodynia. Lead author Yury Miller, professor of medicine at UCSD...

BioCentury | May 31, 2018

Translation in Brief

Sourcing neural precursor cells

...developed iPS cell-derived transplants for spinal cord injury that require minimal immunosuppression. Researchers from the University of California San Diego...
...display similar immunogenic properties. In a study published in Science Translational Medicine in May, a UCSD...

BioCentury | May 25, 2018

Company News

Amgen, partners to bring cancer management system to rural Kentucky

...to under-served areas across the U.S. The University of Kentucky Markey Cancer Center and the University of California San Diego...
...Communications Commission, Washington, D.C. National Institutes of Health, Bethesda, Md. Business: Cancer Allison Johnson Amgen Inc. National Cancer Institute University of California San Diego University...

BioCentury | Apr 19, 2018

Emerging Company Profile

Engine power

...LLC, Cambridge, Mass. Recursion Pharmaceuticals Inc., Salt Lake City, Utah Tango Therapeutics Inc., Cambridge, Mass. University of California San Diego...
...the National Academy of Sciences (2016) Elizabeth Eaton, Staff Writer Engine Biosciences Pte. Ltd. Massachusetts Institute of Technology Mayo Clinic University of California San Diego...

BioCentury | Apr 13, 2018

Targets & Mechanisms

Meeting the burden

...cancers, including PDAC ( No. 4802 ). On the other hand, a presentation from a University of California San Diego...
...Predicine Inc., Hayward, Calif. Tango Therapeutics Inc., Cambridge, Mass. Unity Biotechnology Inc., San Francisco, Calif. University of California San Diego...
...Research GlaxoSmithKline plc Guardant Health Inc. Horizon Discovery Group plc Ideaya Biosciences Inc. OrigiMed Inc. Pfizer Inc. Predicine Inc. Tango Therapeutics Inc. Unity Biotechnology Inc. University of California San Diego Foundation...

BioCentury | Apr 10, 2018

Emerging Company Profile

Yeasty does it

...compound for less than $2,000 in two to three days. BiocipherX spun out from the University of California San Diego...
...SGPA platform, which was developed by Jaeger and Trey Ideker, a professor of medicine at UCSD...
...CEO: Philipp Jaeger Patents: None issued Companies and Institutions Mentioned BiocipherX Inc., San Diego, Calif. University of California San Diego...

BioCentury | Mar 30, 2018

Emerging Company Profile

Skin-to-skin

...in mice colonized with S. aureus . Gallo is a professor of dermatology at the University of California San Diego...
...opposed to an Rx product.” MatriSys has an exclusive, worldwide license its pipeline candidates from UCSD...
...IIa Founded: 2015 by Mark Wilson, Richard Gallo, Lou Bookbinder and Gilbert Keller University collaborators: University of California San Diego...

BioCentury | Mar 16, 2018

Preclinical News

New Cas enzyme can edit RNA, target tau

...pipeline of candidates based on the work of interim CEO Gene Yeo and colleagues at University of California San Diego...
...destroy RNA (see BioCentury Innovations, Sept. 14, 2017) . Sandi Wong Arbor Biotechnologies Inc. Salk Institute for Biological Studies University of California San Diego Locanabio...

BioCentury | Mar 13, 2018

Distillery Therapeutics

Cancer

...online Feb. 28, 2018 doi:10.1126/sciadv.aao4502 CONTACT: Richard L. Gallo, University of California San Diego, La Jolla, Calif. email: rgallo@ucsd.edu Alicia Parker University of California San Diego Melanoma...

BioCentury | Feb 22, 2018

Finance

Bigger BRAIN Initiative

...Network (BICCN). One pilot, conducted by researchers from the Salk Institute for Biological Studies and University of California San Diego (UCSD)...
...million to researchers from University of Texas MD Anderson Cancer Center, Johns Hopkins University and UCSD...
...network operates separately from NIA’s Alzheimer’s Disease Cooperative Study (ADCS), a clinical network run by UCSD...

BioCentury | Feb 16, 2018

Clinical News

Galmed's Aramchol misses in Phase IIa for HIV-associated NAFLD

...serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. The trial was sponsored by the University of California San Diego...

BioCentury | Jan 25, 2018

Translation in Brief

Remote-controlled CARs

...in the Proceedings of the National Academy of Sciences last week, a group from the University of California San Diego...
...found exclusively on tumors, said study author Peter Yingxiao Wang, a professor of bioengineering at UCSD...
...reach a depth of about 10 cm, while light can penetrate only micrometers or millimeters. UCSD...

BioCentury | Dec 08, 2017

Targets & Mechanisms

Epiphenomena at ASH

...This week, Fate announced a partnership to develop off-the-shelf, CAR-targeted NK cell therapies with the University of California San Diego...
...University, Stanford, Calif. Tufts University, Medford, Mass. University of California Los Angeles, Los Angeles, Calif. University of California San Diego...
...AG Obsidian Therapeutics Inc. Oryzon Genomics S.A. Otsuka Pharmaceutical Co. Ltd. Poseida Therapeutics Inc. Stanford University Tufts University University of California Los Angeles University of California San Diego University...

BioCentury | Dec 01, 2017

Company News

Avrobio acquires cystinosis program from GenStem

...exclusive, worldwide rights to cystinosis gene therapy AVR-RD-04. Financial details are not disclosed. GenStem, a University of California San Diego...
...gene therapy. Avrobio Inc., Cambridge, Mass. GenStem Therapeutics Inc., San Diego, Calif. Business: Renal Allison Johnson Avrobio Inc. University of California San Diego AVR-RD-04 GenStem...

BioCentury | Nov 30, 2017

Targets & Mechanisms

All-purpose HSCs

...most eyes are on hematopoietic stem cells for their ability to treat blood cancers, a UCSD...
...the lab of Stephanie Cherqui, an associate professor in the Department of Pediatrics at the University of California San Diego...
...through the nanotubes to treat the diseased cells (see “HSC Highways”). Figure: HSC highways A University of California San Diego...

BioCentury | Nov 30, 2017

Emerging Company Profile

A versatile sponge

...such as α- and γ-toxins, and about 80 different families of toxins that target RBCs. University of California San Diego...
...LLC, San Diego, Calif. Cellics Therapeutics Inc., San Diego, Calif. Critical Pressure Ltd., Cambridge, U.K. University of California San Diego...
...toxin-absorbing nanosponges for local treatment of methicillin-resistant Staphylococcus aureus infection.” Advanced Materials (2015) Lauren Martz, Senior Writer University of California San Diego...

BioCentury | Nov 30, 2017

Translation in Brief

New Therapeutic Targets and Biomarkers: November 2017

...suggest inhibiting the metabolic enzymes NADK or SUCLA2 could help treat K-Ras (KRAS)-mutant colorectal cancer. University of California San Diego...

BioCentury | Nov 27, 2017

Distillery Therapeutics

Cancer

...Sept. 27, 2017 doi:10.1158/0008-5472.CAN-17-2043 CONTACT: Tariq M. Rana, University of California San Diego, La Jolla, Calif. email: trana@ucsd.edu Karen Tkach Tuzman University of California San Diego K-Ras...

BioCentury | Nov 16, 2017

Emerging Company Profile

YAP off, YAP on

...activate YAP signaling, and is based on work from co-founder Kun-Liang Guan’s lab at the University of California San Diego...
...of breast cancer, head and neck cancer and melanoma. Guan is professor of pharmacology at UCSD...
...by Sofie Qiao, Tim Shannon, Edward Hu, Kun-Liang Guan, Bin Liu, Sheng Ding University collaborators: University of California San Diego...

BioCentury | Nov 14, 2017

Distillery Therapeutics

Cancer

...online Nov. 8, 2017 doi:10.1038/nature24302 CONTACT: Michael Karin, University of California San Diego, La Jolla, Calif. email: karinoffice@ucsd.edu Karen Tkach Tuzman University of California San Diego Immunoglobulin...

BioCentury | Nov 08, 2017

Preclinical News

IgA-expressing cells suppress anti-tumor immunity in NASH-driven HCC

...can be eliminated from the liver by PD-L1 blockade. The study, led by researchers at University of California San Diego...
...block their recruitment to prevent or treat HCC in patients with chronic liver inflammation. Karen Tkach Tuzman durvalumab Imfinzi nivolumab Opdivo University of California San Diego AstraZeneca...

BioCentury | Nov 06, 2017

Distillery Therapeutics

Cardiovascular

...published online Nov. 6, 2017 doi:10.1038/nm.4428 CONTACT: Kevin King, University of California San Diego, La Jolla, Calif. email: krking@ucsd.edu Allison Johnson University of California San Diego cGAMP...

BioCentury | Nov 02, 2017

Product R&D

Sweet specificity

...by its academic founder, Ajit Varki, a professor of cellular & molecular medicine at the University of California San Diego...
...Inc. (NASDAQ:MNTA), Cambridge, Mass. National Cancer Institute (NCI), Bethesda, Md. Siamab Therapeutics Inc., Newton, Mass. University of California San Diego...
...for Cancer Research Boehringer Ingelheim GmbH European Organization for Research and Treatment of Cancer National Cancer Institute Siamab Therapeutics Inc. University of California San Diego CD44 Mucin...

BioCentury | Oct 27, 2017

Preclinical News

Syros, UCSD team identifies pancreatic cancer targets

...Researchers from Syros Pharmaceuticals Inc. (NASDAQ:SYRS) and the University of California San Diego identified targets for pancreatic cancer by using...

BioCentury | Oct 26, 2017

Tools & Techniques

Ripe for enhancement

...a study on pancreatic super-enhancers performed in collaboration with Andrew Lowy, a professor at the University of California San Diego...
...University, Stanford, Calif. Syros Pharmaceuticals Inc. (NASDAQ:SYRS), Cambridge, Mass. University of California Berkeley, Berkeley, Calif. University of California San Diego...

BioCentury | Oct 06, 2017

Company News

Camino receives $10.8M grant to treat addiction

...will fund a deal with Sanford Burnham Prebys Medical Research Institute (La Jolla, Calif.) and University of California San Diego...
...to treat cocaine and nicotine addiction. Sanford Burnham will optimize lead compounds and their analogs, UCSD...
...Pharma LLC , San Diego, Calif. Business: Neurology Shannon Lehnbeuter SBP-0069330 Camino Pharma LLC Sanford Burnham Prebys Medical Discovery Institute University of California San Diego Metabotropic...

BioCentury | Oct 05, 2017

Translation in Brief

Chronic neuroprotection

...preclinical testing for CNS indications. According to CEO Val Goodfellow, Califia and collaborators at the University of California San Diego...
...with activity in neurodegeneration models." Journal of Medicinal Chemistry (2015) Winnie Pong, Staff Writer Califia Bio Inc. Genentech Inc. University of California San Diego Roche c-jun...

BioCentury | Sep 30, 2017

Product Development

Running interference

...mechanisms. John Rossi’s comments about APOLLO were more sanguine, as was Steven Dowdy of the University of California San Diego...
...Therapeutics Ltd., London, U.K. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Solstice Biologics LLC, San Diego, Calif. University of California San Diego...